Novo Nordisk faces a turbulent period with a 20% stock drop, Eli Lilly’s US market dominance, and Canada’s first generic Ozempic approval signaling pricing risks.<\/p>\n
The Danish pharmaceutical giant Novo Nordisk is navigating one of its most turbulent periods in years. While the market for weight-loss and diabetes drugs continues to expand at breakneck speed, the company\u2019s stock has been battered, losing nearly 20% of its value since January. At roughly \u20ac36 per share, it sits far below its 52-week high, and the pressure is mounting from all sides\u2014competition, pricing erosion, and a looming generic threat.<\/p>\n
A Market Share Shift in the US<\/p>\n
The battle for dominance in the lucrative GLP-1 market is tilting decisively toward Eli Lilly. In the United States, Lilly now commands roughly 60% of the market, leaving Novo Nordisk with just under 40%. The overall pie has grown by nearly a third, which cushions both players, but the shift in share is stark. Outside the US, the race is far closer, with the two companies splitting the international market almost evenly.<\/p>\n
Novo Nordisk does hold a clear edge in oral therapies. Its pill-based weight-loss treatments generate over 18,000 weekly prescriptions, dwarfing Lilly\u2019s newer rival product, which manages only a fraction of that volume. This strength in tablets could prove pivotal as the market evolves.<\/p>\n
A Valuation Gap That Screams Opportunity\u2014or Risk<\/p>\n
The stock market is pricing the two rivals very differently. Novo Nordisk trades at a price-to-earnings ratio of just 12, while Eli Lilly commands a multiple of 26\u2014more than double. That gap is well below Novo Nordisk\u2019s historical average, and some analysts see it as a sign of deep undervaluation. The stock closed recently at around $42, a staggering 70% drop from its mid-2024 record high.<\/p>\n
Should investors sell immediately? Or is it worth buying Novo Nordisk?<\/a><\/p>\n But the low valuation also reflects real headwinds. Management has warned that revenue and operating profit could fall by up to 13% on a currency-adjusted basis this year. That would mark the first annual decline in nine years, driven by intense price competition and the arrival of new generics.<\/p>\n The Canadian Generic Test<\/p>\n The most immediate threat comes from Canada, where Health Canada has authorized the first generic version of Ozempic, manufactured by Dr. Reddy\u2019s Laboratories. The approval is limited to Type 2 diabetes and explicitly excludes the weight-loss drug Wegovy. Canada is the world\u2019s second-largest market for semaglutide, and Novo Nordisk\u2019s patent protection there expired in early January.<\/p>\n More generics are lining up. Sandoz and Teva have also filed applications, with Sandoz aiming for a June launch. Historical patterns suggest that a single generic typically drives prices down to 75% of the original, while three competitors can slash them to 35%. For now, the US core market remains insulated\u2014key patents there don\u2019t expire until the early 2030s\u2014but Canada is being watched as a bellwether.<\/p>\n Analyst Evan Seigerman of BMO Capital Markets calls it a critical test case. Investors will scrutinize how the original product holds up against copycats, even if a global threat is not yet imminent.<\/p>\n Pipeline Progress Offers a Counterweight<\/p>\n Amid the competitive noise, Novo Nordisk is making strides in its pipeline. The drug Etavopivat, targeting sickle cell disease, delivered positive Phase 3 results, reducing painful crises by 27% and nearly doubling the time to the first event compared to placebo. The company plans to file for regulatory approval in the second half of the year.<\/p>\n This rare disease program provides a bright spot, but it is unlikely to offset the immediate pressures on the core business.<\/p>\n What to Watch on May 6<\/p>\n All eyes are now on Monday, when Novo Nordisk reports first-quarter results before the US market opens. Analysts expect earnings to decline by roughly 5%, and the report will offer the first hard data on pricing pressure and market share trends. A relative strength index of 23 signals that the stock is deeply oversold, but that alone does not guarantee a rebound.<\/p>\n